Another year http://andromeda2030.com/index.php/nexium-news-sq75 nexium tabletas 20 mg "There are still millions of people around the globe who have poorly controlled LDL-C," said George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. "Three years ago, our Phase 1 trials generated the first clinical evidence that blocking PCSK9 could markedly lower cholesterol levels in humans. Today, it is very gratifying to be able to report the first Phase 3 data for this promising potential new class of lipid-lowering agents. It is important to point out that these are just the first of a large amount of data yet to come from our extensive ODYSSEY Phase 3 program."
(携帯) |